Brexafemme
Drug Anti-Infective
NDC 75788-115-04
General payments
$4,460
Research payments
$0
Through program year 2025, $4,460 in general payments and $0 in research payments were reported against Brexafemme (Anti-Infective).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $668 | 11 |
| 2024 | General | $2,779 | 34 |
| 2023 | General | $1,014 | 11 |
Breakdown
The top 5 of 9 recipients; each share is of general payments naming this product in 2025.
The top 5 of 6 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
56 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.